Evaluation of bivalirudin-based anticoagulation for extracorporeal membrane oxygenation, including patients with COVID-19

Open Access

Table 1

Institutional protocol of bivalirudin for mechanical circulatory support.

Renal Function	Initial bivalirudin infusion rate
CrCl > 60 mL/min	0.08 mg/kg/h
CrCl 30–60 mL/min	0.05–0.08 mg/kg/h
CrCl <30 mL/min or CRRT/iHD	0.03–0.05 mg/kg/h

Low Intensity (Goal aPTT 45–60)	High Intensity (Goal aPTT 60–80)
Common Uses (but not limited to): Early LVAD post-operative days (e.g., Post-op day 0–2) Higher bleeding risk VV ECMO	Common Uses (but not limited to): Later LVAD post-operative days (e.g., Post-op day 3+) Lower bleeding risk High thrombotic risk Patients with additional anticoagulation indication(s)

CrCl: Creatinine clearance; LVAD: Left ventricular assist device.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.